Rx News For Physicians Archive

2007
MDeNews™ June
2007
Brand v. Generic Antidepressants for the Treatment of Depression: What Does the Evidence Really Say?
June 27, 2007
Safety Information - Ortho Evra© and desogestrel-containing Oral Contraceptives
Find out what the FDA analysis of Ortho Evra and desogestrel-containing contraceptives
concluded.
March 30, 2007
MDeNews™ March 2007
The ADOPT Study: Implications for the Choice of Initial Oral Hypoglycemic Therapy
Safety Information
- Ortho Evra© and desogestrel-containing
Oral Contraceptives
Find out what the FDA analysis of Ortho Evra and desogestrel-containing contraceptives
concluded.
March 30, 2007
Generics First – Statin Program
In just the last year, high-quality statin generics that are able to provide
up to 40% LDL-C lowering have become available.
February 2, 2007
MDeNews™ January
2007
In response to requests for clinical updates, generic medication
release dates and special member program changes we’ve developed MDeNews™. To
receive this quarterly electronic newsletter send an email to MDeNews@regence.com. Please
include the provider’s: (1) name; (2) email address; and (3) contact phone number. Providers
may also request the newsletter by calling 1 (877) 356-7763 and leaving
the above information.
January 11, 2007
2006
FDA
Alert - "At-Home" Genetic Tests May Lack Scientific Validity
Direct-to-consumer marketed genetic tests may lack scientific validity and provide
questionable results.
August 8, 2006
The Regence Group Selects McKesson Specialty as Primary
Specialty Pharmacy Provider
McKesson Specialty, a subsidiary of McKesson Corporation, announced today it has been selected by The Regence Group as the primary specialty pharmacy provider for its nearly 3 million covered lives.
April 4, 2006
RegenceRx has selected McKesson Specialty, a subsidiary of McKesson Corporation, as primary specialty pharmacy provider
RegenceRx has selected McKesson Specialty, a subsidiary of McKesson Corporation, as the primary specialty pharmacy provider for its nearly 3 million covered lives. McKesson Specialty will replace Regence's current specialty pharmacy vendor.
March 31, 2006
2005
MedWatch – Strattera and Increased Risk of Suicidal Thinking
The U.S. Food and Drug Administration (FDA) directed Eli Lilly and Company to include warning statements for Strattera (atomoxetine), alerting health care providers of an increased risk of suicidal thinking in children and adolescents.
September 30, 2005
MedWatch-The FDA Safety Information and Adverse Event Reporting Program
|